📣Le CARPEM organise le 14 juin 2024 un congrès grand public sur l'IA, un nouvel outil au service de la lutte contre le cancer. Nous vous y attendons nombreux, n'hésitez pas à diffuser cette information autour de vous! Programme et inscription gratuite 👉siric-carpem.e-congres.com/fr/

✏Contribuez | Nous évaluons le #médicament PLUVICTO (Lutécium (177Lu) vipivotide tétraxétan) renouvellement en accès précoce post-AMM pour le traitement du cancer de la #prostate métastatique résistant à la castration progressif positif... swll.to/uhBMT

TROPICS-4 (sacituzumab govitecan vs chemo) in heavily pretreated bladder cancer missed OS. Many drugs have failed in this space (personal experience +++). Managing toxicity is important. Earlier treatment & combinations may yield different results #ASCO24 gilead.com/news-and-press…

JUST IN: Durvalumab extends EFS and OS In muscle-invasive bladder cancer —major news with IO moving earlier stages in balder cancer ! OncoAlert Oncology Times Oncology Brothers Tom Powles Targeted Oncology OncLive.com astrazeneca.com/media-centre/p…

Une jeune fille contacte le 3018 ☎️ car un garçon la menace de diffuser ses n*des 🔞

Campagne de lutte contre l’antisémitisme réalisée grâce à ⁦Arthur_Officiel⁩ et Maurice Lévy pour la ⁦Licra⁩ . Bravo pour ce film fort en ce #14Juillet Liberté Égalité Fraternité

#ARANOTE positive #darolutamide Ph III trial in mHSPC OncoAlert ESMO - Eur. Oncology #ESMO24 neal shore Neeraj Agarwal, MD, FASCO businesswire.com/news/home/2024…®-darolutamide-from-Phase-III-trial-in-men-with-metastatic-hormone-sensitive-prostate-cancer-mHSPC

CHMP gives a positive recommendation for Enfortumab Vedotin and Pembrolizumab in 1st line advanced UC. Paving the way for use in Europe. merck.com/news/merck-rec…

France just won the #Paris2024 gold medal in rugby sevens and then did this !!!

C’est déjà la fin de ces Jeux Olympiques historiques. 💔 On a vécu des moments d’émotion et de beauté absolument surréalistes. Alors je vous propose de les revivre ensemble ! THREAD des moments sportifs les plus marquants de ces Jeux de #Paris2024. 👇

J&J's Balversa earns EU nod as first precision therapy for FGFR3-altered bladder cancer firstwordpharma.com/story/5888528

The EMA has approved Enfortumab Vedotin and pembrolizumab for 1st line urothelial cancer. It supersedes 1st platinum based therapy as the new standard of care in Europe. astellas.com/en/news/29371?…

Thread of satisfying photos for perfectionists 1. Moon bridge

Just in 👉 Journal of Clinical Oncology Benefit of Whole-Pelvis Radiation ☢️ for Patients With #MIBC ascopubs.org/doi/10.1200/JC… 👇👇👇TWEETORIAL 👇👇👇

SBRT for localized prostate cancer: Game-changing results! A Phase 3 trial shows SBRT is non-inferior to standard radiotherapy for achieving freedom from clinical/biochemical failure. Late toxicity rates were similar. Treatment completed in 5 fractions vs. 39 for CRT. SBRT

Comparative effectiveness of iRARC vs. ORC for #BladderCancer: findings from a real life study show better perioperative outcomes with similar cancer control and ureteroileal stricture outcomes after iRARC Thomas Seisen doi.org/10.1111/bju.16…

FDA Approves Subcutaneous Nivolumab in Advanced or Metastatic Solid Tumors onclive.com/view/fda-appro…

1/5 Sharing our Clinical Cancer Research work establishing serum CA-125 as a biomarker for #RenalMedullaryCarcinoma. This is now the first cancer-associated blood biomarker to become standard of care and used globally for a #kidneycancer : aacrjournals.org/clincancerres/… The V Foundation for Cancer Research Chris Johnson Foundation Inc.

Happy to share the team latest investigation of BIONIK trial showing unexpectedly that angiogenic signature is associated with response to immunotherapy in ccRCC, against the current dogma! @igbmc thanks to Stéphane Oudard nature.com/articles/s4169…

This is a major story from #ASCO25. Randomized phase 3 trial of time of day of immunotherapy infusion. Randomized to infusion before or after 3pm. Early infusion far superior: PFS 11.3 vs 5.7 HR 0.42, OS HR 0.45! Impactful, pragmatic, not costly. This should be a bigger story.